Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies
The Journal of Immunology · 15.02.2024 · 212 (4) · 529-533
DOI: 10.4049/jimmunol.2300647 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 27.12.2023. Verfasst von Theo Rispens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, …. Hauptthemen laut MEDLINE: Antigens, CD20, Antibodies, Monoclonal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
One reason for a lack of response to rituximab as well as infusion-related anaphylactic adverse events is the development of antidrug Abs to rituximab. Besides rituximab, a number of other therapeutic Abs targeting CD20 are nowadays available as alternatives. In this study, we investigated the potential cross-reactivity of (human) anti-rituximab Abs to three other anti-CD20 mAbs: ofatumumab, obinutuzumab, and ocrelizumab. In 25 cases of anti-rituximab Abs, cross-reactivity was examined using both direct binding assays and inhibition immunoassays. Although no cross-reactivity was observed to ofatumumab or obinutuzumab, 8 of 25 samples also showed reactivity toward ocrelizumab in at least one of the two assays. Furthermore, in three cases of anti-ocrelizumab Abs, cross-reactivity to rituximab was observed in an inhibition immunoassay, albeit not in a direct binding assay. Our results suggest that obinutuzumab or ofatumumab are safe anti-CD20 alternatives in case of the presence of anti-rituximab Abs. It is advisable to proceed cautiously if switching from rituximab to ocrelizumab (or vice versa) is considered in case these alternatives may not be available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
- Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands.
- Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology, Amsterdam, the Netherlands.
- Antibodies and Immunogenicity, Sanquin Diagnostic Services, Amsterdam, the Netherlands.
ORCID-Profile: Joep Killestein, Karien Bloem
Zitieren
APA
Rispens, T., Kuijpers, T. W., Killestein, J., van Kempen, Z. L. E., & Bloem, K. (2024). Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies. The Journal of Immunology, 212(4), 529-533. https://doi.org/10.4049/jimmunol.2300647
Vancouver
Rispens T, Kuijpers TW, Killestein J, van Kempen ZLE, Bloem K. Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies. The Journal of Immunology. 2024;212(4):529-533. doi:10.4049/jimmunol.2300647
BibTeX
@article{Rispens2024,
author = {Rispens, Theo and Kuijpers, Taco W and Killestein, Joep and van Kempen, Zoé L E and Bloem, Karien},
title = {Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies},
journal = {The Journal of Immunology},
year = {2024},
volume = {212},
number = {4},
pages = {529--533},
doi = {10.4049/jimmunol.2300647}
}
EUVIMED